ReviewInternational urology and nephrology2011
Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data.
Review in International urology and nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Sclerosing encapsulating peritonitis causing fatal bowel obstruction.BMJ case reports · 2023Article
- Encapsulated Peritoneal Sclerosis Masquerading as an Abdominal Catastrophe in Peritoneal Dialysis Therapy.Cureus · 2021Article
- The effect of rituximab on encapsulated peritoneal sclerosis in an experimental rat modelTurkish journal of medical sciences · 2020Article
- Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF-β1 Inhibition.International journal of molecular sciences · 2020Review
- Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.International journal of molecular sciences · 2019Review
- Abdominal Cocoon Syndrome: Two Cases of an Anatomical Abnormality.Case reports in surgery · 2019Article
- Hypoxia, cytokines and stromal recruitment: parallels between pathophysiology of encapsulating peritoneal sclerosis, endometriosis and peritoneal metastasis.Pleura and peritoneum · 2018Review
- Risk factors for drainage-requiring ascites after refractory peritonitis in peritoneal dialysis patients.International urology and nephrology · 2016Article
- Sclerosing Encapsulating Peritonitis: Review.Sultan Qaboos University medical journal · 2016Review
- Encapsulating peritoneal sclerosis in an Italian center: thirty year experience.Journal of nephrology · 2016Article
- Accurate definition and management of idiopathic sclerosing encapsulating peritonitis.World journal of gastroenterology · 2015Review
- Overcoming the Underutilisation of Peritoneal Dialysis.BioMed research international · 2015Review
- Dialysate cancer antigen 125 in long-term peritoneal dialysis patients.Clinical and experimental nephrology · 2014Review
- Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease.Frontiers in physiology · 2014Review
- Encapsulating peritoneal sclerosis: a rare complication of peritoneal dialysis in Al-ain, United arab emirates.Case reports in nephrology and urology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Encapsulating peritoneal sclerosis (EPS) is an infrequent but serious complication of peritoneal dialysis (PD). The pathogenesis is unknown but speculation is ongoing. The current management of EPS focuses on prevention and treatment of the inflammatory and fibrotic changes at the level of the peritoneal membrane with immunosuppressive and antifibrotic agents, respectively. This article reviews the currently available human and animal data on potential agents to prevent and/or treat EPS. We propose a strategy for early diagnose EPS in an attempt to avoid the development of the full-blown and potentially life-threatening clinical syndrome of EPS. Future research should focus on studying potential prophylactic and therapeutic agents in humans in large, multicenter, randomized trials but also on early detection of EPS in the inflammatory phase by means of biomarkers and the establishment of a composite EPS score.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.